Kringle Pharma Balance Sheet

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	1,588	1,619	2,313	2,136	2,756	2,137
Cash & Short-Term Investments	1,588	1,619	2,313	2,136	2,756	2,137
Cash Growth	-15.80%	-30.00%	8.29%	-22.50%	28.97%	1.67%
Accounts Receivable	-	-	-	7	-	6
Other Receivables	32	60	57	74	67	76
Receivables	32	60	57	81	67	82
Inventory	250	250	294	364	349	315
Prepaid Expenses	-	20	23	14	11	12
Other Current Assets	94	106	68	22	24	88
Total Current Assets	1,964	2,055	2,755	2,617	3,207	2,634
Long-Term Investments	24	23	1	1	1	1
Other Long-Term Assets	-	1	1	-	-	-
Total Assets	1,988	2,079	2,757	2,618	3,208	2,635
Accounts Payable	-	1	1	-	1	-
Accrued Expenses	-	15	21	5	2	3
Current Income Taxes Payable	89	21	37	173	54	32
Other Current Liabilities	321	72	69	31	105	92
Total Current Liabilities	410	109	128	209	162	127
Other Long-Term Liabilities	631	662	522	388	258	2
Total Liabilities	1,041	771	650	597	420	129
Common Stock	134	64	11	97	59	51
Additional Paid-In Capital	2,968	2,888	2,835	3,095	3,057	2,755
Retained Earnings	-2,189	-1,672	-756	-1,185	-331	-301
Comprehensive Income & Other	34	28	17	14	3	1
Shareholders' Equity	947	1,308	2,107	2,021	2,788	2,506
Total Liabilities & Equity	1,988	2,079	2,757	2,618	3,208	2,635
Net Cash (Debt)	1,588	1,619	2,313	2,136	2,756	2,137
Net Cash Growth	-15.80%	-30.00%	8.29%	-22.50%	28.97%	1.67%
Net Cash Per Share	225.20	236.63	361.45	396.27	567.55	514.49
Filing Date Shares Outstanding	7.4	7.02	6.81	5.41	5.38	4.33
Total Common Shares Outstanding	7.4	7.02	6.81	5.41	5.38	4.33
Working Capital	1,554	1,946	2,627	2,408	3,045	2,507
Book Value Per Share	128.06	186.38	309.37	373.88	518.16	578.13
Tangible Book Value	947	1,308	2,107	2,021	2,788	2,506
Tangible Book Value Per Share	128.06	186.38	309.37	373.88	518.16	578.13